He is the discoverer of both monoamine oxidase (MAO) B inhibitors l-deprenyl (Selegiline) and rasagiline (Azilect) as anti- ... Biogenic Amines, Neuropsychobiology, Neurochemical Research; Brain Research, CNS Drug Review, Future Drugs, Drugs of Today, and ... He is a discoverer of the anti-Parkinson drugs selelgiline (l-deprenyl) and developer of monoamine oxidase B inhibitor ... Youdim, Moussa B H; Bakhle, Y S (2006). "Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive ...
... although it lacks monoamine transporter affinity and therefore has little effect in monoamine neurons of the central nervous ... Other biogenic amines are present in the central nervous system at very low concentrations in the order of 0.1-10 nm, ... Monoamine autoreceptors (e.g., D2 short, presynaptic α2, and presynaptic 5-HT1A) have the opposite effect of TAAR1, and ... In cells expressing both human TA1 and a monoamine transporter (DAT, SERT or NET) signalling via TA1 is enhanced [26,48,50-51 ...
Sánchez C, Hyttel J (1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines ... "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of ... as it can lower the seizure threshold TCAs should not be used concomitantly or within 14 days of treatment with monoamine ...
Exogenous compounds in this family are degraded too rapidly by monoamine oxidase to be active at all but the highest doses. ... October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome ... Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal ...
It is substantially weaker in inhibiting the reuptake of and inducing the release of the monoamine neurotransmitters compared ... "Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue". The Journal of ...
Classes of neurotransmitters include amino acids, monoamines, and peptides. Monoamines are synthesized by altering a single ... VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the ... a type of monoamine transporter located on synaptic vesicles within monoamine neurons. An antagonist is a chemical that acts ... Serotonin is a monoamine neurotransmitter. Most is produced by and found in the intestine (approximately 90%), and the ...
Negus SS, Brandt MR, Mello NK (October 1999). "Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine ... "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a ... Indatraline hydrochloride (Lu 19-005) is an antidepressive agent and non-selective monoamine transporter inhibitor that blocks ... October 2006). "A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy ...
Nishimura M, Sato K, Okada T, Schloss P, Shimada S, Tohyama M (1998). "MK-801 blocks monoamine transporters expressed in HEK ... 1994). "Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate ... Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S, Tohyama M (1998). "Ketamine inhibits monoamine transporters ... In addition to their high affinity for the main site of the monoamine transporters, several competitive transporter substrates ...
Monoamine-depleting agents, Pyrogallol ethers, VMAT inhibitors, Methoxy compounds, Methyl esters, Heterocyclic compounds with 5 ... and alpha-methyltyrosine on brain biogenic amines". Federation Proceedings. 35 (14): 2558-2562. PMID 11134. v t e v t e ( ...
"Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine ... Methamnetamine (also known as methylnaphetamine, MNA, MNT and PAL-1046) is a triple monoamine releasing agent and N-methyl ...
Psilocin is broken down by the enzyme monoamine oxidase to produce several metabolites that can circulate in the blood plasma, ... reacts with biogenic amines present in the body to produce MAOIs related to tetrahydroisoquinoline and β-carboline. Tobacco ... It is structurally related to serotonin, a monoamine neurotransmitter which is a derivative of the amino acid tryptophan. ... van Amsterdam J, Talhout R, Vleeming W, Opperhuizen A (2006). "Contribution of monoamine oxidase (MAO) inhibition to tobacco ...
Richelson E, Pfenning M (September 1984). "Blockade by antidepressants and related compounds of biogenic amine uptake into rat ... and very weak or negligible monoamine reuptake inhibitor. These actions appear to confer a profile similar to that of iprindole ... Randrup A, Braestrup C (August 1977). "Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the ... "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol. 340 (2-3 ...
Green AL, El Hait MA (April 1980). "p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro ... Tseng LF, Menon MK, Loh HH (May 1976). "Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic ... Ask AL, Fagervall I, Ross SB (September 1983). "Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat ... Ask AL, Fagervall I, Ross SB (September 1983). "Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat ...
They are not considered addictive and are somewhat preferable to the monoamine oxidase inhibitors (MAOIs). The side effects of ... "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". ... Rénéric JP, Lucki I (March 1998). "Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced ... "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of ...
The initial step in the breakdown can be catalyzed by either of the enzymes monoamine oxidase (mainly monoamine oxidase A) or ... Biochemistry of Biogenic Amines. Springer. pp. 1-35. ISBN 978-1-4684-3171-1. Griffith RK (2013). "Chapter 10: Adrenergic ... I. Demonstration of monoamines in the cell bodies of brain stem neurons". Acta Physiologica Scandinavica Supplementum. 232 ( ... Monoamine oxidase inhibitors are antidepressants that inhibit the metabolic degradation of norepinephrine as well as serotonin ...
September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine ... "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". ...
Caution should be observed when combining bupropion with a monoamine oxidase inhibitor (MAOI), as it may result in hypertensive ... "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". ... It should be avoided in individuals who are taking monoamine oxidase inhibitors (MAOIs). The label recommends that caution ... Feinberg SS (November 2004). "Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible ...
It is not likely that changes in the metabolism of the biogenic amines alone will account for the complex phenomena of normal ... Studies of depleted levels of monoamine neurotransmitters show an association with depression and other psychiatric disorders, ... The dysfunction in serotonin and other monoamine neurotransmitters (norepinephrine and dopamine) correspond with certain mental ...
"Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". ... "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of ...
... acts as a nonselective and irreversible inhibitor of monoamine oxidase. Regarding the isoforms of monoamine ... Tyramine is a biogenic amine produced as a (generally undesirable) byproduct during the fermentation of certain tyrosine-rich ... Gillman PK (2016). "Monoamine oxidase inhibitors: a review concerning dietary tyramine and drug interactions" (PDF). ... This leads to an increase in the availability of monoamines, such as serotonin, norepinephrine, and dopamine, epinephrine as ...
Rothman RB, Ananthan S, Partilla JS, Saini SK, Moukha-Chafiq O, Pathak V, Baumann MH (June 2015). "Studies of the biogenic ... In the most widely accepted model for monoamine transporter function, sodium ions must bind to the extracellular domain of the ... Miller GM (January 2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine ... Monoamine transporter Norepinephrine transporter Serotonin transporter Glutamate transporter ENSG00000276996 GRCh38: Ensembl ...
Tseng LF, Menon MK, Loh HH (May 1976). "Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic ... although with a slightly different ratio of monoamine release, being a combined serotonin, dopamine, and norepinephrine ...
These changes in the biogenic amino levels can cause behavioral changes such as changes in response to external stimuli ... linked to the synthesis of monoamines and/ or the physiological consequences of their bio-availability. This altered ...
Monoamine releasing agent Marona-Lewicka D, Nichols DE (June 1994). "Behavioral effects of the highly selective serotonin ... "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology. ... is an SRA with less significant or no efficacy in producing neurotransmitter efflux at other types of monoamine neurons. SSRAs ... are SNDRAs and non-selective serotonin receptor agonists that were originally thought to be monoamine oxidase inhibitors and ...
Tessel RE, Rutledge CO (May 1976). "Specificity of release of biogenic amines from isolated rat brain tissue as a function of ... 3-Fluoroethamphetamine (3-FEA) is a stimulant drug of the amphetamine class which acts as a releasing agent of the monoamine ...
... are TAAR1 agonists and vesicular monoamine transporter 2 inhibitors that can enter monoamine neurons; this allows them to ... VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the ... Monoamine oxidase inhibitors: Concomitant use of MAOIs and central nervous system stimulants such as lisdexamfetamine can cause ... It is also contraindicated in patients who have used a monoamine oxidase inhibitor (MAOI) within the last 14 days. Amphetamine ...
... to either stop transporting monoamines altogether (via transporter internalization) or transport monoamines out of the neuron; ... Similarly, urinary biogenic trace amine PEA levels could be a biomarker for the diagnosis of ADHD,20,57,58 for treatment ... VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the ... These agencies indicate that people who have experienced allergic reactions to other stimulants or who are taking monoamine ...
In humans, PEA is metabolized by phenylethanolamine N-methyltransferase (PNMT), monoamine oxidase A (MAO-A), monoamine oxidase ... The biogenic amines, phenethylamine and tyramine, are N-oxygenated by FMO to produce the N-hydroxy metabolite, followed by a ... and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons. To a lesser extent, it also acts as a ... Similarly, urinary biogenic trace amine PEA levels could be a biomarker for the diagnosis of ADHD,20,57,58 for treatment ...
In any case, there is also clinical and animal evidence that trimipramine does not inhibit the reuptake of monoamines. Unlike ... Randrup A, Braestrup C (1977). "Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine ... Haenisch B, Hiemke C, Bönisch H (2011). "Inhibitory potencies of trimipramine and its main metabolites at human monoamine and ... The atypicality of trimipramine in relation to its lack of monoamine reuptake inhibition is described as challenging the ...
Negus SS, Mello NK, Blough BE, Baumann MH, Rothman RB (February 2007). "Monoamine releasers with varying selectivity for ... June 2005). "Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self- ...